ETS1 Orchestrates a Hybrid EMT Program Driving Metastasis and Immune Evasion.

ETS1 drives a hybrid EMT program that promotes metastasis and immune evasion in upper aerodigestive squamous cell carcinoma, with high expression linked to poor survival.

• Why it matters: Understanding the transcriptional programs behind tumor heterogeneity is crucial for developing targeted therapies for aggressive cancers that resist current treatments and evade immune responses.
• What they did: Single-cell RNA sequencing of tumor cells and patient samples identified ETS1 as a master regulator of a hybrid EMT program, activating prometastatic and immune-suppressive genes in over 100 tumors.
• The result: Targeting ETS1-high tumors with HSP90 inhibitors like alvespimycin suppressed ETS1 activity, offering a promising strategy to combat metastasis and overcome immunotherapy resistance.